secwatch.observer — SEC 8-K summary
======================================

Issuer:     NeuroPace Inc (NPCE)
CIK:        0001528287
Form:       8-K
Filed at:   2021-11-10T23:59:59+00:00
Accession:  0001528287-21-000017
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NeuroPace Q3 revenue drops 19% to $10.3M; net loss widens to $8.1M
------------------------------------------------------------------

- Q3 total revenue $10.3M down 19% YoY; initial implant revenue $7.8M down 15%.
- Net loss $8.1M vs $4.1M loss in prior year; gross margin 72.6% vs 75.0%.
- Updated FY2021 guidance: total revenue $44-44.5M (7-8% growth), initial implant $33-33.5M.
- Received IDE approval for clinical study to expand indication to primary generalized epilepsy.
- Added Lisa Andrade to Board; submitted PMA supplement for longer battery life claim (nearly 11 yrs).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1528287/000152828721000017/0001528287-21-000017-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1528287/000152828721000017/npce-20211110.htm
  HTML page:      https://secwatch.observer/filing/0001528287-21-000017

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer